May 4, 2021 – MolecuLight Corp., announced that its MolecuLight i:X fluorescence wound imaging device has received an Innovative Technology contract from Vizient, Inc. (Irving, TX).
The new Innovative Technology contract for MolecuLight i:X signifies to Vizient members the device’s unique qualities that potentially bring improvement to the healthcare industry.
The MolecuLight i:X performs digital wound area measurement, allowing for the accurate documentation of wounds, the company says. It is the only point-of-care imaging device that allows clinicians to visualize elevated bacterial burden (>104 CFU/g) in wounds, along with clinical signs and symptoms (CSS).
As the presence of elevated bacterial burden precludes wounds from healing1, having a point-of-care device such as the i:X provides valuable information in real-time to inform clinician decision-making.
Published results from a recent 350-patient, 14-site study showed that the clinical standard of care use (CSS) only detected 15% of wounds with elevated bacterial burden, while addition of the i:X to standard of care led to a 400% improvement in detecting these wounds.